Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$1.31 USD
-0.03 (-2.24%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $1.32 +0.01 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Editas Medicine (EDIT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.91 | $11.00 | $1.00 | 266.42% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Editas Medicine comes to $4.91. The forecasts range from a low of $1.00 to a high of $11.00. The average price target represents an increase of 266.42% from the last closing price of $1.34.
Analyst Price Targets (11)
Find the top stocks with the greatest price target potential and Zacks Rank of 1 or 2
Broker Rating
Editas Medicine currently has an average brokerage recommendation (ABR) of 2.59 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 2.12 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, five are Strong Buy, representing 29.41% of all recommendations. A month ago, Strong Buy represented 47.06%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 6 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 1 | 1 |
Hold | 10 | 10 | 8 | 8 | 8 |
Sell | 1 | 1 | 1 | 0 | 0 |
Strong Sell | 1 | 0 | 0 | 0 | 0 |
ABR | 2.59 | 2.35 | 2.12 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
12/16/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
12/13/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
12/13/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Hold |
12/13/2024 | Not Identified | Not Identified | Hold | Strong Buy |
12/13/2024 | Not Identified | Not Identified | Hold | Hold |
12/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/11/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Hold |
11/6/2024 | Evercore Partners | Liisa A Bayko | Hold | Strong Buy |
11/5/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
11/4/2024 | Not Identified | Not Identified | Hold | Hold |
10/3/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.59 |
ABR (Last week) | 2.35 |
# of Recs in ABR | 17 |
Average Target Price | $4.18 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 65 of 251 |
Current Quarter EPS Est: | -0.30 |
EDIT FAQs
Editas Medicine, Inc. (EDIT) currently has an average brokerage recommendation (ABR) of 2.59 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms.
The average price target for Editas Medicine, Inc. (EDIT) is $4.18. The current on short-term price targets is based on 11 reports.
The forecasts for Editas Medicine, Inc. (EDIT) range from a low of $1 to a high of $8. The average price target represents a increase of $219.08 from the last closing price of $1.31.
The current UPSIDE for Editas Medicine, Inc. (EDIT) is 219.08%
Based on short-term price targets offered by 11 analysts, the average price target for Editas Medicine comes to $4.91. The forecasts range from a low of $1.00 to a high of $11.00. The average price target represents an increase of 266.42% from the last closing price of $1.34.